Active, not recruitingNot applicableNCT02984566
Liver Ablative Radiotherapy Utilising Kilovoltage Intrafraction Monitoring (KIM)
Studying Rare tumor of liver and intrahepatic biliary tract
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Sydney
- Principal Investigator
- Tim Wang, DrWestmead Hospital
- Intervention
- Kilovoltage Intrafraction Monitoring(device)
- Enrollment
- 32 enrolled
- Eligibility
- 18-85 years · All sexes
- Timeline
- 2020 – 2026
Study locations (4)
- Nepean Hospital, Penrith, New South Wales, Australia
- Westmead Hospital, Westmead, New South Wales, Australia
- Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
- Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02984566 on ClinicalTrials.govOther trials for Rare tumor of liver and intrahepatic biliary tract
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07356531Clinical Trial Evaluating the Safety and Efficacy of Tumor Thermosensitive Embolic Agent in Transcatheter Arterial Chemoembolization for Primary Liver CancerJIANGSU SHENMING Medical Technology CO., Ltd
- ACTIVE NOT RECRUITINGNCT04145141National Translational Science Network of Precision-based Immunotherapy for Primary Liver CancerNational Cancer Institute (NCI)
See all trials for Rare tumor of liver and intrahepatic biliary tract →